Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Pharma
Madrigal builds launch infrastructure for MASH drug Rezdiffra
Despite a reimbursement hurdle from the VA, Madrigal is still targeting 80% commercial coverage for its MASH drug Rezdiffra by year-end.
Angus Liu
May 7, 2024 11:56am
Docs sing praises of Madrigal's Rezdiffra, predict rapid uptake
Apr 8, 2024 7:45am
FDA approves first drug for MASH in Madrigal's Rezdiffra
Mar 14, 2024 3:56pm
NASH market fattening up as wait for liver treatments drags on
Dec 4, 2023 10:49am
Meet Madrigal, which wants to be your liver's No. 1 fan
Nov 15, 2023 9:40am
NASH market holds 'enormous untapped potential,' analysts say
Aug 10, 2023 10:00am